Azitra Secures $10.5M Financing to Fund Cosmetic and Protein Platforms
AZTR•Azitra raised $10.5 million in March plus up to $21 million from warrant exercises to fuel a strategic shift toward shorter‐timeline commercial markets leveraging its microbial genetic engineering platform. New initiatives include ATR‐COSF recombinant filaggrin for cosmetic anti‐aging applications and recombinant protein products targeting a $1 billion research enzymes market.
1. Strategic Reorientation and Financing
In March Azitra closed a $10.5 million equity financing and secured up to $21 million via warrants, enabling a shift toward near‐term value initiatives across cosmetic, biotech, and therapeutic applications by leveraging its synthetic biology and AI-driven microbial genetic engineering platform.
2. ATR-COSF Cosmetic Ingredient Program
The company repurposed its filaggrin technology from the ATR-01 therapeutic pipeline to develop ATR-COSF, a recombinant filaggrin protein targeting fine lines and wrinkles, with ex vivo skin studies underway and a clinical trial expected to complete in late 2026 for potential 2027 commercialization.
3. Recombinant Protein Commercial Platforms
Leveraging in-licensed FHCC minicircle plasmids, Azitra is engineering high-value proteins such as T7 RNA Polymerase and TEV Protease, addressing an estimated $1 billion market in research and biologics manufacturing, with proof-of-concept milestones slated over the next 36 months for partnerships and licensing opportunities.
4. Clinical Pipeline Adjustments
Azitra continues enrolling patients in its ATR-04 live biotherapeutic for EGFR inhibitor-associated rash, adding MD Anderson as a trial site, while pausing ATR-12 Netherton syndrome enrollment to conserve capital and redirect resources toward higher value ATR-COSF development.
